THE NANT CANCER VACCINE

haNK® and t-haNKTM lead
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System

THE NANT CANCER VACCINE

haNK® and t-haNK™
THE NANT CANCER VACCINE
Harnessing the Power of Our Immune System

The NANT Cancer Vaccine applies multiple aspects of cancer therapy utilizing therapeutic agents to transition cancer cells from an escape phase back to an equilibrium or elimination phase. These therapeutic agents are synergistically tailored to a patient’s tumor and intended to act in a coordinated manner to modulate the tumor microenvironment to reduce immune suppression, increase stress and damage recognition signals in the tumor, induce and enhance innate and adaptive immune responses, and generate immune memory in order to achieve improved response rates and patient outcomes.

The NANT Cancer Vaccine investigational clinical protocol is a three step process:

  • The first step seeks to transition an escape phase of the tumor by delivering a therapeutic agent or agents that reduces immune suppression in the tumor microenvironment.
  • The second step, the elimination phase, involves the treatment with a second therapeutic agent or agents to enhance an adaptive immune response and/or an innate immune response.
  • The third step, the equilibrium phase, is focused on maintaining response by administering a third therapeutic agent or agents that favorably biases the adaptive immune response towards an activated immune state.

To learn more about Nant Cancer Vaccine Clinical Trials


CONTACT NANTKWEST
CLICK HERE

NK-92 ®️ CELLS FOR ASSAYS
CLICK HERE